Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ChimeriVax-JE and STAMARIL
NCT00982137Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2004
- Primary completion
- Apr 2005
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (4 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Japanese Encephalitis Seroconversion at Day 60, Number of Participants With Yellow Fever Seroconversion at Day 60 and 2 more. Started Jul 2004; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00982137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982137.